SCHEMBL3538892

SCHEMBL3538892

NNC(=O)C(=O)Nc1ccc(N2CCC(C(=O)O)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
KDM4E B2RXH2 4/20 0.47
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ABL1 P00519 1/20 0.44
DGAT1 O75907 1/20 0.43
KCNH2 Q12809 1/20 0.43
MCHR1 Q99705 1/20 0.43
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
NEK2 P51955 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543293 0.87 KDM4E (0.52) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL3539892 0.85 SYK (0.45) MAPTKDM4EDGAT1KCNH2MCHR1
SCHEMBL3541057 0.84 ALDH1A1 (0.47) MAPTKDM4ELMNAHTTALDH1A1
SCHEMBL13009559 0.83 DGAT1 (0.45) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL3541406 0.83 DGAT1 (0.57) KDM4ELMNAHTTALDH1A1KMT2A
SCHEMBL4500215 0.81 MAPT (0.61) MAPTLMNAHTTALDH1A1DGAT1
SCHEMBL13009516 0.80 DGAT1 (0.46) MAPTKDM4EALDH1A1DGAT1KCNH2
SCHEMBL326799 0.76 LMNA (0.55) MAPTKDM4ELMNAHTTALDH1A1
SCHEMBL3544514 0.76 LMNA (0.55) KDM4ELMNAHTTKMT2AABL1
SCHEMBL3547590 0.76 MAPT (0.42) MAPTKDM4ELMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 MAPT 2115/4885KDM4E 3511/4885LMNA 3296/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 MAPT 1986/4885KDM4E 3382/4885LMNA 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.